AGWCA
PTCT icon

Annis Gardner Whiting Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$304 – 1375
2025
Q4 		$304 Buy
+4
New +$291 ﹤0.01% 1140

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's PTCT Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 4 shares — an estimated $304 sold.

Annis Gardner Whiting Capital Advisors first reported a position in PTCT in Q4 2025 and held it in 1 quarter. The position peaked at $304 in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 4 PTC Therapeutics shares in Q1 2026, an estimated $304.
  • Annis Gardner Whiting Capital Advisors first reported a position in PTC Therapeutics in Q4 2025 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's PTC Therapeutics position peaked at $304 in Q4 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.